Figure 1.

Adoptive immunotherapy as an addition to standard treatment for GBM patients. GBM patients receive standard of care therapy consisting of surgery followed by chemo- and radiotherapy. However, tumor recurrence is inevitable. In GBM patients, who are CMV seropositive, virus-specific T cell immunotherapy can be used as consolidative treatment to enhance intrinsic immune responses against viral antigen expressing tumor cells. If effective, adoptive immunotherapy has the potential to prolong progression free survival or even prevent relapse in GBM patients.